Chief Operating Officer
Abveris and AbX Biologics
The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.
Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.
Who Should Watch:
- Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
- Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.
Learn more about Sartorius solutions for mAb Discovery & Development at www.sartorius.com/mAb-development.